{
  "id": 430246,
  "title": "Molbio Diagnostics IPO: What Brokerages say: Buy or avoid?",
  "url": "https://urgent.news/2026/08/10/molbio-diagnostics-ipo-what-brokerages-say-buy-or-avoid",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-10T01:50:21.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/molbio-diagnostics-ipo-what-brokerages-say-buy-or-avoid/article71324539.ece"
  },
  "original_language": "en",
  "account": "The initial public offering (IPO) of Molbio Diagnostics, a Temasek and Motilal Oswal Private Equity-backed company, opened today with a price band of Rs 768-807 per share. The ₹939.70 crore IPO closes on Wednesday, with up to 50% reserved for Qualified Institutional Buyers (QIBs) and retail investors allowed to bid up to 35% of the net offer. The company has reserved approximately 20,500 shares for its employees at a discount of ₹76 per share. Molbio Diagnostics, based in Goa, offers point-of-care diagnostics for 30 diseases, including tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company's innovative 'Truenat' platform, a battery-operated polymerase chain reaction system, delivers rapid, accurate diagnoses in resource-limited settings. With a strong competitive position and supportive R&D, patent portfolio, and global presence, Molbio Diagnostics appears to be a promising long-term investment opportunity.",
  "summary": "Issue opens today at Rs 768-807 price band",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}